Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
Sofopoulos M, Fortis SP, Vaxevanis CK, Sotiriadou NN, Arnogiannaki N, Ardavanis A, Vlachodimitropoulos D, Perez SA, Baxevanis CN. Sofopoulos M, et al. Among authors: fortis sp. Cancer Immunol Immunother. 2019 Nov;68(11):1733-1745. doi: 10.1007/s00262-019-02407-8. Epub 2019 Oct 9. Cancer Immunol Immunother. 2019. PMID: 31598757 Free PMC article.
Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.
Janssen N, Fortis SP, Speigl L, Haritos C, Sotiriadou NN, Sofopoulos M, Arnogiannaki N, Stavropoulos-Giokas C, Dinou A, Perez S, Pawelec G, Baxevanis CN, Shipp C. Janssen N, et al. Among authors: fortis sp. Breast Cancer Res Treat. 2017 Jan;161(1):51-62. doi: 10.1007/s10549-016-4037-z. Epub 2016 Oct 27. Breast Cancer Res Treat. 2017. PMID: 27787640
Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics.
Fortis SP, Vaxevanis CK, Mahaira LG, Sofopoulos M, Sotiriadou NN, Dinou A, Arnogiannaki N, Stavropoulos-Giokas C, Thanos D, Baxevanis CN, Perez SA. Fortis SP, et al. Cancer Immunol Immunother. 2019 Jan;68(1):57-70. doi: 10.1007/s00262-018-2252-7. Epub 2018 Oct 1. Cancer Immunol Immunother. 2019. PMID: 30276443 Free PMC article.
Prostate cancer: any room left for immunotherapies?
Baxevanis CN, Fortis SP, Perez SA. Baxevanis CN, et al. Among authors: fortis sp. Immunotherapy. 2019 Feb;11(2):69-74. doi: 10.2217/imt-2018-0159. Immunotherapy. 2019. PMID: 30727800 No abstract available.
50 results